Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oligonucleotides (ONs) are therapeutic macromolecules with great potential for the treatment of neurological conditions, including spinal muscular atrophy (SMA), a neurodegenerative disease. However, the neurovascular unit severely limits their distribution to the neural parenchyma of the brain and the spinal cord. Cell-penetrating peptides (CPPs) can be conjugated to oligonucleotides to increase their delivery across biological barriers. In this chapter, we describe the synthesis and conjugation of CPPs to oligonucleotides, and the use of a severe SMA mouse model to test in vivo the efficacy of CPP-delivered oligonucleotides, using ELISA, western blot, and TaqMan™ RT-qPCR assays.

Original publication

DOI

10.1007/978-1-0716-1752-6_31

Type

Chapter

Publication Date

2022

Volume

2383

Pages

491 - 513

Keywords

Antisense oligonucleotides, Cell-penetrating peptide, In vivo pup administrations, Peptide oligonucleotide conjugates, Spinal muscular atrophy, Survival motor neuron, Taiwanese SMA mouse model, Animals, Cell-Penetrating Peptides, Disease Models, Animal, Mice, Muscular Atrophy, Spinal, Oligonucleotides, Oligonucleotides, Antisense